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Abstract 
Objectives. We sought to investigate the potential impact of preoperative short-term mechanical circulatory support 
(MCS) with extracorporeal devices on postoperative outcomes after emergency heart transplantation (HT). 
Methods. We conducted an observational study of 669 patients who underwent emergency HT in 15 Spanish 
hospitals between 2000 and 2009. Postoperative outcomes of patients bridged to HT on short-term MCS (n = 101) 
were compared with those of the rest of the cohort (n = 568). Short-term MCS included veno-arterial extracorporeal 
membrane oxygenators (VA-ECMOs, n = 23), and both pulsatile-flow (n = 53) and continuous-flow (n = 25) 
extracorporeal ventricular assist devices (VADs). No patient underwent HT on intracorporeal VADs. 
Results. Preoperative short-term MCS was independently associated with increased in-hospital postoperative 
mortality (adjusted odds-ratio 1.75, 95% CI 1.05–2.91) and overall post-transplant mortality (adjusted hazard-ratio 
1.60, 95% CI 1.15–2.23). Rates of major surgical bleeding, cardiac reoperation, postoperative infection and primary 
graft failure were also significantly higher among MCS patients. Causes of death and survival after hospital discharge 
were similar in MCS and non-MCS candidates. Increased risk of post-transplant mortality affected patients bridged 
on pulsatile-flow extracorporeal VADs (adjusted hazard-ratio 2.21, 95% CI 1.48–3.30) and continuous-flow 
extracorporeal VADs (adjusted hazard-ratio 2.24, 95% CI 1.20–4.19), but not those bridged on VA-ECMO (adjusted 
hazard-ratio 0.51, 95% CI 0.21–1.25). 
Conclusions. Patients bridged to emergency HT on short-term MCS are exposed to an increased risk of postoperative 
complications and mortality. In our series, preoperative bridging with VA-ECMO resulted in comparable post-
transplant outcomes to those of patients transplanted on conventional support. 
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1. Introduction 
The number of patients bridged to heart transplantation (HT) under mechanical circulatory support (MCS) 
is growing worldwide [1]. In this setting, the goal of MCS is not only to increase patient's life expectancy, 
but also to improve their quality of life, end-organ function and nutritional status, so favoring better post-
transplant outcomes. However, the potential benefits of MCS may be counteracted by device-related 
complications [2] such as infection, embolism, bleeding, or immune sensitization. 
Intracorporeal left ventricular assist devices (LVADs) constitute the current standard-of-care to 
provide long-term MCS to HT candidates whose clinical status deteriorates while waiting for an organ 
donor. According to the Interagency Registry for Mechanically Assisted Circulatory Support 
(INTERMACS), 1-year and 2-year survival rates of patients who currently receive a continuous-flow 
intracorporeal LVAD as a bridge-to-transplantation respectively exceed 80% and 70% [3]. In a pooled 
analysis of 12 observational studies, patients bridged to HT on intracorporeal LVADs showed comparable 
post-transplant survival to candidates bridged on optimal medical therapy, including intravenous 
inotropes [4]. A propensity-score-matched analysis of the United Network for Organ Sharing (UNOS) 
database reached a similar conclusion [5]. 
The implantation of an intracorporeal LVAD, however, is not the best therapeutic option for all HT 
candidates that require MCS. Postoperative mortality after LVAD surgery is significantly increased when 
the device is implanted in severely acute decompensated patients [6], or in the presence of right 
ventricular failure [7]. In most of these cases, the implantation of a short-term extracorporeal device 
constitutes a more suitable initial approach. Short-term MCS usually results in a rapid hemodynamic 
stabilization, and favors the recovery of the end-organ function, allowing the patient to undergo a 
destination procedure such as HT or long-term VAD implantation with a reasonable expectancy of 
survival [8]. Worldwide, the use of short-term extracorporeal devices as a direct bridge to HT is an 
uncommon strategy, as it implies that a suitable organ donor must become available for the patient within 
a few days. In Spain, however, it is frequently resorted to, as the use of long-term intracorporeal LVADs 
is subject to tight economic restrictions. 
The potential impact of preoperative short-term extracorporeal MCS on post-transplant outcomes has 
been less studied than in the case of intracorporeal LVADs. Previous analyses included a small number of 
patients supported on short-term devices, and showed conflicting results. Some authors found that 
patients bridged to HT on extracorporeal MCS were exposed to an increased risk of post-transplant 
mortality [4] and [9], but others reported that they have similar post-transplant outcomes to candidates 
bridged on intravenous inotropes [10]. The potential impact of different extracorporeal devices on post-
transplant outcomes has not yet been determined. 
In view of gaps in knowledge, we sought to study the impact of preoperative short-term MCS on post-
transplant outcomes. For this purpose, we analyzed in-hospital postoperative complications, long-term 
survival, and causes of death of patients who underwent emergency HT in Spain during the past decade 
after being supported with short-term extracorporeal VADs or veno-arterial extracorporeal membrane 
oxygenators (VA-ECMOs), and compared them with a control group of patients who underwent 
emergency HT without preoperative MCS during the same period. 
2. Methods 
2.1. Setting of the study 
We conducted a multi-institutional, observational study based on a historical cohort of patients who 
underwent first, single-organ HT under a high-emergency status – the so-called status 0 – in the Spanish 
organ donor allocation system (Organización Nacional de Trasplantes, ONT) between January 1st, 2000 
and December 31st, 2009. 
During the study period, listing criteria for ONT status 0 required permanent hospitalization due to a 
non-reversible cardiac disease with an imminent risk of death, and either continuous dependence on short-
term extracorporeal MCS, an intra-aortic balloon pump (IABP), or invasive mechanical ventilation 
together with intravenous inotropes, or the presence of recurrent life-threatening ventricular arrhythmias 
despite optimal medical therapy. Heart transplant candidates listed under ONT status 0 had priority over 
all other candidates to get the first suitable donor heart available in the system. Long-term intracorporeal 
VADs were not available in Spain during the study period. 
2.2. Short-term mechanical circulatory support 
In this study, the definition of short-term MCS refers to extracorporeal devices intended for left 
ventricular, right ventricular, or biventricular circulatory assistance for a maximum period of a few weeks 
(usually < 30 days). This included continuous-flow extracorporeal VADs (Levitronix Centrimag, 
Medtronic Biomedicus, Medos HIA-VAD, Jostra Rotaflow and Impella 5L), pulsatile-flow extracorporeal 
VADs (Abiomed BVS5000, Abiomed AB5000, Berlin Heart Excor, and Thoratec), and VA-ECMO 
(Maquet PLS, Maquet Cardiohelp, Medos Deltastream, and Medtronic Biomedicus). Patients bridged to 
emergency HT solely under IABP support were included in the control group. 
2.3. Data collection and variables 
Data for the study were extracted from a multicentre database [11] that contains detailed clinical 
information about all consecutive patients aged > 18 years who underwent emergency HT between 2000 
and 2009 in 15 out of the 16 Spanish hospitals that had an active HT program at that time. This database 
was assembled with data collected from the prospective Spanish National Heart Transplantation Registry 
[12] and completed on the basis of an individualized review of clinical records. For the present analysis, 
patients who underwent re-transplantation or double-organ transplantation were not considered. The 
institutional review board approved the study protocol. 
2.4. Post-transplant outcomes 
In-hospital postoperative outcomes of the study were major surgical bleeding, need for cardiac 
reoperation, need for dialysis, postoperative infection, primary graft failure, isolated right ventricular 
failure and in-hospital postoperative mortality. Long-term outcomes were post-transplant survival and 
discharge-conditioned post-transplant survival. Causes of death were collected from autopsy studies or, if 
not available, from medical certificates of death. Specific definitions of study outcomes have been 
detailed previously [11] and are provided as Supplementary data. 
2.5. Statistical analysis 
In this manuscript, categorical variables are presented as proportions and compared by means of the Chi-
squared test, while continuous variables are presented as mean ± standard deviation and compared by 
means of the T-Student test. 
Post-transplant survival curves of patients bridged to HT with or without short-term MCS were 
estimated by means of the Kaplan–Meier method and compared by means of the log-rank test, both in the 
entire cohort and in the subcohort of individuals who survived the early postoperative period and were 
discharged alive from hospital. Follow-up was censored at the time of death or the last clinical visit, up to 
a maximum of 5 years after HT. 
Adjusted hazard-ratios (HRs) for overall post-transplant mortality and discharge-conditioned post-
transplant mortality were obtained by means of backward stepwise multivariable Cox's proportional 
hazards models. Candidate variables that entered multivariable analyses were those that showed a 
statistically significant association (p < 0.05) with each one of these outcomes in univariable analyses and 
others considered as potential confounders on the basis of previous literature and clinical experience. In a 
similar manner, the association between short-term MCS and in-hospital postoperative outcomes was 
assessed by means of backward stepwise multivariable logistic regression models. 
In view of the asymmetric distribution of MCS and non-MCS patients over the study period, this 
was arbitrarily divided into two eras, the early era (years 2000 to 2006), and the recent era (years 2007 to 
2009). Specific subanalyses about the impact of short-term MCS on post-transplant survival during both 
eras were conducted. 
Statistical significance was set as a p-value < 0.05, and all contrasts were two-tailed. Statistical 
analysis was performed with SPSS Statistics 20. 
3. Results 
3.1. Study population 
According to the Spanish National Heart Transplantation Registry, 2956 patients aged > 18 years 
underwent HT in our country between 2000 and 2009. Seven hundred and twenty-four patients underwent 
HT under ONT status 0, with 711 of them at the 15 hospitals participating in the study. After the 
exclusion of 29 patients who underwent re-transplantation and 13 patients who underwent simultaneous 
double-organ transplantation, the final study sample comprised 669 patients. 
One hundred and one (15%) patients were bridged to HT on short-term MCS. Twenty-five patients 
from 9 centers were supported on continuous-flow extracorporeal VADs, 53 patients from 8 centers were 
supported on pulsatile-flow extracorporeal VADs, and 23 patients from 3 centers were supported on VA-
ECMO. Extracorporeal VADs implanted included 43 univentricular devices (4 right VADs and 39 
LVADs), and 35 biventricular devices. Among the 568 patients of the control group, 373 (66%) were 
supported on an IABP before HT. 
Fig. 1 shows the distribution of patients over the study period according to preoperative support. The 
proportion of patients undergoing HT under short-term MCS was 10.4% during the period 2000–2003, 
8.9% during the period 2004–2006 and 25.6% during the period 2007–2009 (p for linear trend < 0.001). 
In view of this asymmetric distribution, the study period was arbitrarily divided into two eras, the early 
era (years 2000 to 2006), and the recent era (years 2007 to 2009). The number (percentage) of MCS 
patients who underwent HT during the early and the recent era was, respectively, 43 (43%) and 58 (57%). 
 
  
 
 
 
Fig. 1. Distribution of patients by the type of preoperative support and year of transplantation. VAD, ventricular assist device. VA-
ECMO, veno-arterial extracorporeal membrane oxygenator. 
3.2. Clinical characteristics of patients with or without MCS 
Table 1 shows the clinical characteristics of recipients, donors, and HT procedures in the two study 
groups. Patients in the MCS group were younger and more frequently women than patients in the control 
group. The MCS group showed a higher prevalence of previous cardiac surgery and post-cardiotomy 
shock, while the prevalence of diabetes mellitus was higher in the control group. Mean waiting-list time 
for emergency HT was around 5 days in both study groups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Clinical variables related to recipients, donors and heart transplant procedures. 
 
MCS 
N = 101 
Control 
N = 568 
p 
    
Demographics    
Age (years), mean ± standard deviation 48 ± 13 50.9 ± 12 0.022 
Women 38% 16% < 0.001 
Waiting-list time (days) 5.8 ± 7 5.2 ± 7 0.42 
    
Clinical history    
Ischemic heart disease 44% 49% 0.30 
Acute myocardial infarction 35% 32% 0.66 
Diabetes 6% 16% 0.011 
Hypertension 23% 27% 0.35 
Previous cardiac surgery 50% 17% < 0.001 
Post-cardiotomy shock 39% 16% < 0.001 
Implantable defibrillator 12% 23% 0.012 
Cardiac resynchronization therapy 3% 8% 0.083 
Cardiac arrest 20% 20% 0.92 
Preoperative infection 35% 27% 0.12 
Preoperative INTERMACS status   < 0.001 
Status 1 39% 28%  
 Status 2 50% 39%  
 Status 3 11% 28%  
 Status 4 1% 5%  
    
Supportive therapies    
Intravenous inotropes 94% 94% 0.88 
Inotropic indexa 63 ± 82 23 ± 46 < 0.001 
Dialysis 9% 7% 0.60 
Mechanical ventilation 87% 38% < 0.001 
    
Laboratory    
Hemoglobin (g/l), at transplantation 10.2 ± 2.5 11.5 ± 2 < 0.001 
Creatinine (mg/dl), peak 1.65 ± 0.8 1.63 ± 0.9 0.82 
Creatinine (mg/dl), at transplantation 1.35 ± 0.7 1.32 ± 0.7 0.90 
Bilirubin (mg/dl), peak 2.4 ± 2.1 1.9 ± 1.6 0.047 
Bilirubin (mg/dl), at transplantation 1.64 ± 1.4 1.63 ± 1.5 0.97 
Aspartate aminotransferase (IU/l), peak 482 ± 1249 207 ± 631 0.038 
Aspartate aminotransferase (IU/l), at transplantation 182 ± 552 154 ± 574 0.65 
Alanine aminotransferase (IU/l), peak 389 ± 1032 194 ± 622 0.013 
Alanine aminotransferase (IU/l), at transplantation 157 ± 471 147 ± 551 0.87 
    
Hemodynamics    
Ejection fraction (%) 19 ± 11 21 ± 9 0.022 
Cardiac index (ml/min/m2) 2.1 ± 0.7 2.2 ± 0.7 0.32 
Central venous pressure (mm Hg) 14 ± 6 13 ± 7 0.25 
Capillary wedge pressure (mm Hg) 23 ± 9 25 ± 9 0.13 
Mean pulmonary pressure (mm Hg) 32 ± 10 33 ± 10 0.23 
    
Heart transplant surgery    
Cold ischemic time (min) 219 ± 58 211 ± 58 0.24 
Bypass time (min) 160 ± 73 131 ± 50 < 0.001 
    
Donor characteristics    
Female donor 35% 27% 0.10 
Donor on inotropes 78% 77% 0.76 
Donor with cardiac arrest 6% 8% 0.69 
Donor age (years) 36.3 ± 14 36 ± 13 0.82 
    
 
INTERMACS, Interagency Registry for Mechanically Assisted Circulatory Support. UI, international units. MCS, mechanical 
circulatory support. 
a 
Inotropic index [19] was calculated as dopamine dose (μg/kg/min) + dobutamine dose (μg/kg/min) + 10 × milrinone dose 
(μg/kg/min) + 100 × epinephrine dose (μg/kg/min) + 100 × norepinephrine dose (μg/kg/min). 
  
Mechanically supported patients required higher doses of intravenous inotropes and were more 
frequently on ventilator before HT. Patients in the MCS group reached significantly higher peak serum 
levels of bilirubin, aspartate aminotransferase and alanine aminotransferase during the pre-transplant 
hospitalization, but levels were similar in both groups at the time of HT. Peak serum creatinine and 
creatinine at the time of HT were also similar in both study groups. The proportion of patients with 
INTERMACS status 1, 2, 3 and 4 before HT was respectively 39%, 50%, 11% and 1% in the MCS group 
and 28%, 39%, 28% and 5% in the control group. 
Mean bypass time during HT surgery was significantly longer (p < 0.001) in the MCS group 
(160 ± 73 min) than in the control group (131 ± 50 min). No significant differences among groups were 
observed with regard to donor age or cold ischemic times. 
3.3. In-hospital postoperative outcomes 
During the early postoperative period after HT, patients bridged under short-term MCS presented 
significantly higher rates of primary graft failure (36.6% versus 21.3%, p = 0.001), major surgical 
bleeding (30.7% versus 21.5%, p = 0.042), need for cardiac reoperation (21.8% versus 13.2%, p = 0.024), 
and postoperative infection (50.5% versus 38.6%, p = 0.024) than patients in the control group, as shown 
in Fig. 2. Rates of isolated ventricular failure and postoperative dialysis were similar in both groups. 
 
 
 
Fig. 2. Rates of in-hospital postoperative outcomes in patients with or without pre-transplant short-term MCS. MCS, mechanical 
circulatory support. 
By means of multivariable logistic regression, preoperative short-term MCS was identified as an 
independent risk factor for primary graft failure (adjusted odds-ratio (OR) 1.78, 95% confidence interval 
(CI) 1.08–2.94) and cardiac reoperation (adjusted OR 1.93, 95% CI 1.12–3.35). A non-significant trend 
toward increased risk of major surgical bleeding was also observed in MCS patients (adjusted OR 1.55, 
95% CI 0.97–2.50). The association between short-term MCS and postoperative infection lost its 
statistical significance after multivariable adjustment (adjusted OR 1.04, 95% CI 0.65–1.67).  
3.4. Post-transplant survival 
Median post-transplant follow-up was 2.9 years (interquartile rank, 0.2 to 5 years). Overall, 255 (38%) 
patients died, 175 (26%) during in-hospital follow-up and 80 (12%) after hospital discharge. 
Patients in the MCS group had significantly shorter post-transplant survival than patients in the 
control group (log rank p = 0.004, Fig. 3, panel A). By means of multivariable Cox's proportional hazards 
regression (Table 2), preoperative short-term MCS was identified as an independent risk factor for overall 
post-transplant mortality (adjusted hazard-ratio (HR) 1.60, 95% CI 1.15–2.23). 
 
 
 
Fig. 3. Post-transplant survival of patients with or without preoperative short-term MCS. Panel A, overall post-transplant survival. 
Panel B, discharge-conditioned post-transplant survival. CI, confidence interval. HR, hazard ratio. MCS, mechanical circulatory 
support. 
Table 2. Risk factors for post-transplant mortality: multivariable Cox's proportional hazards regression. 
 Adjusted HR (95% CI) p 
   
Age of the recipient (years) 1.012 (1–1.024) 0.049 
Age of the donor (years) 1.014 (1.003–1.024) 0.010 
Diabetes mellitus 1.51 (1.06–2.16) 0.022 
Ischemic heart disease 0.70 (0.53–0.92) 0.011 
Pre-transplant dialysis 2.15 (1.46–3.18) < 0.001 
Pre-transplant short-term MCS 1.60 (1.15–2.23) 0.006 
   
 
CI, confidence interval. HR, hazard ratio. MCS, mechanical circulatory support. 
In-hospital postoperative mortality was significantly higher in the MCS group than in the control 
group (37.6% versus 24.1%, p = 0.004; adjusted OR 1.75, 95% CI 1.05–2.91, Fig. 2). Preoperative short-
term MCS had no significant impact on discharge-conditioned post-transplant survival (log rank p = 0.57; 
adjusted HR 1.19, 95% CI 0.59–2.43, Fig. 3, panel B). 
3.5. Causes of death 
Primary graft failure, infection and non-specified multi-organ failure were the most frequent causes of 
death during the early postoperative period, while rejection (acute and chronic), malignancy and infection 
accounted for the majority of deaths during post-discharge follow-up. Fig. 4 shows the distribution of the 
causes of death in the two study groups. 
 
 
 
Fig. 4. Causes of death in the study groups. Panel A, causes of death during the in-hospital postoperative period. Panel B, causes of 
death after hospital discharge. MCS, mechanical circulatory support. 
3.6. Transplant eras 
As shown in Fig. 5, short-term MCS was associated with increased post-transplant mortality only among 
patients who underwent HT during the early era (log rank p = 0.006; adjusted HR 2.14, 95% CI 1.32–
3.46), but not among those who underwent HT during the recent era (log rank p = 0.41, adjusted HR 1.06, 
95% CI 0.66–1.69). In comparison to the early era, the recent era was characterized by significantly 
longer mean waiting-list times (6.1 versus 4.8 days, p = 0.033) and mean cold ischemic times (224 versus 
206 min, p < 0.001), and also by the use of older donors (mean age 38.5 versus 34.7 years, p < 0.001) 
with a higher prevalence of previous cardiac arrest (11.2% versus 5.2%, p = 0.011). 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5. Long-term post-transplant survival of patients with or without preoperative short-term MCS according to transplant eras. 
Panel A, early era (years 2000–2006). Panel B, recent era (years 2007–2009). CI, confidence interval. HR, hazard ratio. MCS, 
mechanical circulatory support. 
3.7. Impact of different devices on post-transplant survival 
Fig. 6 shows the Kaplan–Meier post-transplant survival curves in patients bridged to HT on continuous-
flow extracorporeal VADs, pulsatile-flow extracorporeal VADs, and VA-ECMO (log rank p < 0.001). 
With regard to the control group, post-transplant mortality was significantly increased among patients 
supported on pulsatile-flow extracorporeal VADs (adjusted HR 2.21, 95% CI 1.48–3.30) and continuous-
flow extracorporeal VADs (adjusted HR 2.24, 95% CI 1.20–4.19), but not among those supported on VA-
ECMO (adjusted HR 0.51, 95% CI 0.21–1.25). Both univentricular extracorporeal VADs (adjusted HR 
2.08, 95% CI 1.33–3.24) and biventricular extracorporeal VADs (adjusted HR 2.44, 95% CI 1.46–4.06) 
were associated with increased post-transplant mortality. 
 
 
 
Fig. 6. Long-term post-transplant survival with regard to the type of preoperative support. CF, continuous-flow. CI, confidence 
interval. HR, hazard ratio. PF, pulsatile-flow. VAD, ventricular assist device. VA-ECMO, veno-arterial extracorporeal membrane 
oxygenator. 
Baseline characteristics of patients bridged to HT on VA-ECMO were similar to those of patients 
bridged on extracorporeal VADs, with the exception that former individuals were older (mean age VA-
ECMO group, 54.1 ± 10 years; extracorporeal VAD group, 46.2 ± 13 years; p = 0.008). At transplant 
surgery, patients bridged on VA-ECMO presented shorter mean cold ischemic times (194 ± 57 versus 
226 ± 57 min, p = 0.022) and mean bypass times (139 ± 43 versus 167 ± 79, p = 0.031) than patients 
bridged on extracorporeal VADs.  
4. Discussion 
In our retrospective analysis of a multi-institutional cohort of Spanish patients who underwent emergency 
HT from 2000 to 2009, we found that candidates bridged on short-term MCS with extracorporeal devices 
had shorter post-transplant survival than those bridged with conventional management, which included 
intravenous inotropes, IABP and mechanical ventilation as clinically required. By means of multivariable 
models, we estimated an adjusted hazard-ratio for post-transplant mortality of 1.60 (95% CI 1.15–2.23) 
for MCS patients. To a large extent, this result was driven by an increased incidence of postoperative 
complications and death during the early in-hospital period after HT. Increased mortality risk affected 
patients bridged to HT on pulsatile-flow and continuous-flow extracorporeal VADs, but not those bridged 
on VA-ECMO. Causes of death and long-term survival after hospital discharge were similar in MCS and 
non-MCS patients. 
From clinical experience, surgeons have learnt that HT procedures in MCS patients may be even more 
challenging and bloody than usual. Many devices involve the need for an additional sternotomy and 
require chronic antithrombotic therapy until the day of transplantation. Excessive bleeding during HT 
surgery may lead to prolonged cold ischemic and bypass times, and frequently involve the need for early 
redo cardiac procedures. In this clinical setting, the viability of the vulnerable donor heart may be 
compromised, increasing the risk of primary graft failure and subsequent associated complications, like 
nosocomial infection, multi-organ dysfunction, and death. This reality is well reflected in our study, even 
though mean pre-transplant waiting-list times were really short in both study groups – around 5 days – 
and that no significant differences were noticed between MCS and non-MCS patients with regard to the 
quality of selected donors. 
In general, our findings are concordant with previous literature. A pooled analysis of two 
observational studies [13] and [14] including 461 MCS patients and 9475 controls showed that candidates 
bridged to high-priority HT on short-term extracorporeal VADs had significantly increased post-
transplant mortality, with a relative risk of 1.8 (95% CI 1.5–2.1). Extracorporeal MCS was also identified 
as an independent risk factor for post-transplant mortality in the multi-institutional registries of the 
International Society for Heart and Lung Transplantation [1] and the UNOS [9]. A recent Spanish single-
center study [10], however, reported similar post-transplant outcomes for patients bridged to emergency 
HT with or without short-term MCS in a particular setting of short waiting-list times. Surgical risks 
associated to MCS appear to have a less relevant prognostic impact in the case of stable patients 
undergoing HT on long-term intracorporeal VADs [4] and [5], possibly because they are compensated for 
by the beneficial effects of the device on patient's functional status, nutrition or end-organ function. 
The results of the present investigation should be interpreted with caution, because – similar to 
previous studies – the baseline clinical characteristics of MCS and non-MCS HT candidates were not 
exactly the same. Mechanically supported patients were younger than controls, but the former presented 
with a more severely compromised clinical condition during the pre-transplant hospitalization – higher 
inotropic requirements, more frequent need for mechanical ventilation, larger extent of liver damage – 
that justified the implantation of a short-term device. At the time of HT, however, end-organ function and 
hemodynamic parameters were similar in both study groups, reflecting that MCS was reasonably 
effective in those critically ill individuals. 
Our analysis is affected by a significant era effect. During the earlier years of the study (2000–2006), 
post-transplant mortality was significantly higher among MCS patients than among controls, but this 
difference disappeared during the most recent era (2007–2009). In part, this finding might be attributable 
to a “learning curve” effect, as the results of MCS programs tend to improve with increasing experience. 
Survival differences across eras may also be affected by the use of different mechanical devices. As 
discussed later, post-transplant survival was significantly better among patients bridged on VA-ECMO, 
which were mostly implanted in the recent era, than among those bridged on continuous-flow and 
pulsatile flow devices, which were mainly used in the early era. Finally, it should be noticed that the 
tendency to a similar post-transplant survival in MCS and non-MCS patients observed in the recent era is 
strongly conditioned by a significant increase of post-transplant mortality in the latter group in 
comparison with previous years. In our opinion, this reality reflects a new scenario of increasing scarcity 
of donors, which has made HT teams more willing to accept less-adequate organs from older donors and 
exposed to longer cold ischemic times. 
In our series, post-transplant survival of MCS patients varied significantly according to the type of 
device implanted. Candidates supported on pulsatile-flow and continuous-flow extracorporeal VADs 
showed the highest post-transplant mortality, independently of whether they received univentricular or 
biventricular support. Preoperative bridging with VA-ECMO, however, did not carry a significant 
increase of post-transplant mortality in comparison with the control group. This finding must also be 
interpreted with caution, as the use of VA-ECMO was limited to a small number of patients and centers in 
our series. 
Some advantages make VA-ECMO an attractive option for the initial management of HT candidates 
presenting with a critical clinical condition. Full circulatory and pulmonary support through a peripheral 
vascular access may be provided quickly, at the bedside, and avoiding additional sternotomies. Different 
to other devices, VA-ECMO carries a low risk of thrombotic complications, so patients may be safely 
managed with low-dose unfractionated heparin, without concomitant antiplatelet therapy. To minimize 
bleeding risk, a normal coagulation state may be easily restored just before HT surgery by administering 
intravenous protamine. 
The use of VA-ECMO as a bridge to emergency HT in cardiogenic shock patients offers satisfactory 
results in systems characterized by short waiting-list times [15], as is the case of the Spanish ONT. 
Indeed, VA-ECMO is currently the most frequent device implanted with a “bridge-to-transplant” 
indication in our country [12]. However, the feasibility of this strategy is compromised by the limited 
durability of the device, usually not longer than 2 to 3 weeks. The need for prolonged VA-ECMO 
support, indeed, is associated with a high risk of device-related complications and worsening post-
transplant outcomes [16] and [17]. This implies that, in case the patient does not get a suitable organ 
donor in a short lapse of time, a switch to a durable device must be considered. Until now, the efficacy of 
this “bridge-to-bridge” strategy remains controversial as, in patients under temporary MCS, the 
implantation of an intracorporeal LVAD also carries a high mortality risk [18]. 
The major limitation of our study is its observational, non-randomized design, which implies that its 
usefulness is limited to hypothesis generation. As pointed out, study findings are conditioned by 
significant differences in the baseline clinical characteristics of MCS and non-MCS patients. Despite an 
extensive multivariable adjustment being conducted in order to minimize confusion bias, we cannot rule 
out that other non-tested variables may have influenced the observed statistical associations. Similar to 
previous studies, our analysis is limited to post-transplant outcomes, so no conclusion may be extracted 
about a potential positive impact of MCS on pre-transplant survival. Given the period studied (2000 to 
2009), our investigation reflects a past reality in the rapidly evolving field of MCS and HT, so its results 
might not be extrapolated to the current era. In view of the progressive development of more simple and 
safer mechanical devices and the continuous refinement of organ donor allocation policies, a significant 
improvement of the results of emergency HT in MCS patients is expectable in the future years. Finally, 
because of the peculiarities of the Spanish national organ donor allocation system, the external validity of 
the study is not warranted, so our conclusions might not be applicable to other countries. 
In conclusion, our study supports the hypothesis that patients undergoing emergency HT on short-
term MCS with extracorporeal devices are exposed to an increased incidence of early postoperative 
complications and mortality. Because of significant differences in the baseline clinical characteristics of 
study groups, it is hard to determine whether this finding is attributable to surgical risks associated with 
these kinds of devices or if it is rather due to a worst pre-transplant clinical condition of MCS than non-
MCS candidates. In our series, increased risk of post-transplant mortality affected patients bridged on 
continuous-flow and pulsatile-flow extracorporeal VADs, while post-transplant outcomes of patients 
bridged on VA-ECMO were similar to those of patients undergoing emergency HT under conventional 
therapy. Further investigation is required to clarify the optimal therapeutic pathways for HT candidates 
presenting with a critical clinical condition. 
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